Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings

Life Sciences

Volumn 76, Issue 15, 2005, Pages 1771-1786

  Sonmez Uydes Dogan, B ^a   Topal, Gökçe ^b   Takir, Selçuk ^a   Ilkay Alp, F ^a   Kaleli, Deniz ^a   Özdemir, Osman ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Atorvastatin; Cerivastatin; Endothelium; KATP channels; Mevalonate pathway; Na+ K+ ATP ase; Pravastatin; Rat aorta; Vascular relaxation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ADENOSINE TRIPHOSPHATE; ATORVASTATIN; CERIVASTATIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MEVALONIC ACID; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; OUABAIN; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; MALE; NONHUMAN; RAT; VASCULAR RING; VASODILATATION;

STROPHANTHUS GRATUS;

EID: 13444301315     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.11.002     Document Type: Article

References (33)

1. M. Alvarez de Sotomayor, M.D. Herrera, E. Marhuenda, and R. Andriantsitohaina Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat British Journal of Pharmacology 131 2000 1179 1187
2. +2 homeostasis European Journal of Pharmacology 415 2001 217 224
3. R. Berkels, S.K. Nouri, D. Taubert, H. Bartels, P. Roesen, R. Roesen, and W. Klaus The HMG-CoA reductase inhibitor Cerivastatin enhances the nitric oxide bioavailability of the endothelium Journal of Cardiovascular Pharmacology 42 2003 356 363
4. C. Blume, D. Sabuda-Widemann, J. Pfeilschifter, J. Plum, K. Schrör, B. Grabensee, and K-F. Beck Cerivastatin inhibits proliferation of interleukin-1β-induced rat mesangial cells by enhanced formation of nitric oxide European Journal of Pharmacology 485 2004 1 10
5. P.O. Bonetti, L.O. Lerman, C. Napoli, and A. Lerman Statin effects beyond lipid lowering-are they clinically relevant? European Heart Journal 24 2003 225 248
6. L. Bravo, and M.D. Herrera Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats General Pharmacology 30 1998 331 336
7. F. Degraeve, M. Bolla, S. Blaie, C. Creminon, I. Quere, P. Boquet, S. Levy-Toledano, J. Bertoglio, and A. Habib Modulation of COX-2 expression by statins in human aortic smooth muscle cells The Journal of Biochemical Chemistry 276 2001 46849 46855
8. K. Egashira, Y. Hirooka, H. Kai, M. Sugimachi, S. Suzuki, T. Inou, and A. Takeshita Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolemia Circulation 89 1994 2519-2524
9. M. Endres, U. Laufs, Z.H. Huang, T. Nakamura, P. Huang, M.A. Moskowitz, and J.K. Liao Stroke protection by 3-hydroxy-3-methylglutaryl ((HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase (cerebral blood flow/cerebral ischemia) Proceedings in National Academy of Sciences USA 95 1998 8880 8885
10. +2 mobilization in vascular smooth muscle cells Journal of Cardiovascular Pharmacology 27 1996 383 391
11. Y. Fukata, M. Amano, and K. Kaibuchi Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells Trends in Pharmacological Sciences 22 2001 32 39
12. O. Hernandez-Perera, D. Perez-Sala, and J. Navarro-Antolin Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells Journal of Clinical Investigation 101 1998 2711 2719
13. L.G. Howes, D. Abbott, and N.E. Straznicky Lipoproteins and cardiovascular reactivity British Journal of Clinical Pharmacology 44 1997 319 324
14. K. Ito, T. Kanno, K. Suzuki, K. Masuzawa-Ito, T. Takewaki, H. Ohashi, M. Asano, and H. Suzuki Effects of cromakalim on the contraction and the membrane potential of the circular smooth muscle of guinea-pig stomach British Journal of Pharmacology 105 1992 335 340
15. W.H. Kaesemeyer, R.B. Caldwell, J. Huang, and R.W. Caldwell Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions Journal of American College of Cardiology 33 1999 234 241
16. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
17. A.P. Lea, and D. McTavish Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipideamias Drugs 53 1997 828 847
18. A.M. Lefer, B. Campbell, Y-K. Shin, R. Scalia, R. Hayvard, and D.J. Lefer Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts Circulation 100 1999 178 184
19. A.M. Lefer, R. Scalia, and D.J. Lefer Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease Cardiovascular Research 49 2001 281 287
20. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 231
21. J.G. McCarron, and W. Halpern Potassium dilates rat cerebral arteries by two independent mechanisms American Journal of Physiology 259 1990 H902 H908
22. Y. Mukai, H. Shimokawa, T. Matoba, J. Hiroki, I. Kunihiro, T. Fujiki, and A. Takeshita Acute vasodilator effects of HMG-CoA reductase inhibitors: Involvement of PI3-kinase/Akt pathway and Kv channels Journal of Cardiovascular Pharmacology 42 2003 118 124
23. W. Mück Clinical pharmacokinetics of cerivastatin Clinical Pharmacokinetics 39 2000 99 116
24. G. O'Driscoll, D. Green, and R.R. Taylor Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month Circulation 95 1997 1126 1131
25. P.J. Pentikainen, M. Saraheimo, J.I. Schartz, R.D. Amin, M.S. Schartz, F. Brunner, and I.D. Rogers Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans Journal of Clinical Pharmacology 32 1992 136 140
26. + channels? Trends in Pharmacological Sciences 14 1993 332 337
27. H. Seeger, A.O. Mueck, and T.H. Lippert Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells International Journal of Clinical Pharmacology and Therapeutics 38 2000 270 272
28. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors Arteriosclerosis, Thrombosis and Vascular Biology 21 2001 1712 1719
29. +2 release and vascular reactivity Journal of Cardiovascular Pharmacology 34 1999 95 101
30. C.B. Treasure, L. Klein, W.S. Weintraub, J.D. Talley, M.E. Stillabower, A.S. Ksinski, J. Zhang, S.J. Boccuzzi, J.C. Cedarholm, and R.W. Alexander Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease New England Journal of Medicine 332 1995 481 487
31. A.H. Wagner, T. Köhler, U. Rückschloss, I. Just, and M. Hecker Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation Arteriosclerosis, Thrombosis and Vascular Biology 20 2000 61 69
32. 2+ channels in rat islet β-cells British Journal of Pharmacology 126 1999 1205 1213
33. Z. Yang, T. Kozai, B. Van de Loo, H. Viswambharan, M. Lachat, M.I. Turina, T. Malinski, and T.F. Lüscher HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins Journal of American College of Cardiology 36 2000 1691 1697